An article published in Trials discusses MAGENTA: a study to find if pre-symptomatic testing for age-related macular degeneration risk can lead to quantifiable long-term changes in behavior and lifestyle associated with its lower incidence later in life.
MAGENTA is a single-center study conducted at the John A. Moran Eye Center, the University of Utah, Salt Lake City, Utah, USA. Study subjects will be primarily recruited from clinics at the Moran Eye Center, satellite clinics, and the university community at large. All study visits will be at the Moran Eye Center.Participants must be between 18 and 64 years of age.Participants can have a positive family history of AMD.Have personal history of AMD or have had prior genetic testing for AMD risk.
Importantly, if there are any amendments to the approved protocol which may directly affect the subject’s decision to continue participation in the study, the ICF will be revised to integrate the changes to the protocol, and the participant will be required to endorse the IRB-approved amended ICF. The consent form will request participants’ authorization to disclose pertinent data to regulatory authorities and the IRB, as deemed appropriate by the research team. There will be no collection and storage of biological samples for ancillary studies in the MAGENTA trial.MAGENTA is a phase 2, single-center, prospective, randomized, controlled clinical trial comparing the effect of immediate versus deferred disclosure of AMD genetic risk on biomarkers of ocular and systemic carotenoid status.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
I’m a volunteer at a baby bank - people are struggling, they need our help nowA MUM has revealed the positive impact volunteering at a baby bank has had on her and urges others to do the same. Kate Moran, 33, has been busy raising two children while still volunteering her ti…
Read more »
NHS trailing behind other major nations on life expectancy, study findsResearchers warn Britain's poor performance across several different major disease groups and health conditions including cancer, heart attacks and strokes - judged by preventable deaths - should be a serious concern for political leaders and policymakers.
Read more »
Public health concerns: monitoring e-cigarette sales key to preventing youth tobacco usePublic health concerns: monitoring e-cigarette sales key to preventing youth tobacco use CDCMMWR publichealth health ecigarettes vape vaping tobacco nicotine
Read more »
Europe's battle against Aedes mosquitoes: growing threat of mosquito-borne diseasesEurope's battle against Aedes mosquitoes: growing threat of mosquito-borne diseases ECDC_EU mosquitos infection mosquitoes mosquitoborne disease transmisson publichealth
Read more »
Cracking the code: machine learning models predict ADHD symptoms in youthCracking the code: machine learning models predict ADHD symptoms in youth Nature UMich machinelearning ADHD ADHDsymptoms AI artificialintelligence
Read more »
Factors associated with acute kidney injury among preterm infants administered vancomycin: a retrospective cohort study - BMC PediatricsBackground Vancomycin (VCM) is a widely used antibiotic for the treatment of gram-positive microorganisms, with some nephrotoxic effects. Recent studies have suggested that piperacillin-tazobactam (TZP) aggravates VCM-induced nephrotoxicity in adults and adolescents. However, there is a lack of research investigating these effects in the newborn population. Therefore, this study investigates whether the concomitant use of TZP with VCM use increases the risk of acute kidney injury (AKI) and to explore the factors associated with AKI in preterm infants treated with VCM. Methods This retrospective study included preterm infants with birth weight | 1,500 g in a single tertiary center who were born between 2018 and 2021 and received VCM for a minimum of 3 days. AKI was defined as an increase in serum creatinine (SCr) of at least 0.3 mg/dL and an increase in SCr of at least 1.5 times baseline during and up to 1 week after discontinuation of VCM. The study population was categorized as those with or without concomitant use of TZP. Data on perinatal and postnatal factors associated with AKI were collected and analyzed. Results Of the 70 infants, 17 died before 7 postnatal days or antecedent AKI and were excluded, while among the remaining participants, 25 received VCM with TZP (VCM + TZP) and 28 VCM without TZP (VCM—TZP). Gestational age (GA) at birth (26.4 ± 2.8 weeks vs. 26.5 ± 2.6 weeks, p = 0.859) and birthweight (750.4 ± 232.2 g vs. 838.1 ± 268.7 g, p = 0.212) were comparable between the two groups. There were no significant differences in the incidence of AKI between groups. Multivariate analysis showed that GA (adjusted OR: 0.58, 95% CI: 0.35–0.98, p = 0.042), patent ductus arteriosus (PDA) (adjusted OR: 5.23, 95% CI: 0.67–41.05, p = 0.115), and necrotizing enterocolitis (NEC) (adjusted OR: 37.65, 95% CI: 3.08–459.96, p = 0.005) were associated with AKI in the study population. Conclusions In very low birthweight infants, concomitant use of TZP did not increase the r
Read more »